European Journal of Cancer
Volume 39, Issue 7 , Pages 909-916 , May 2003

Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade

  • R Komdeur

      Affiliations

    • Department of Surgical Oncology, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • B.E.C Plaat

      Affiliations

    • Department of Pathology, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • W.T.A van der Graaf

      Affiliations

    • Department of Medical Oncology, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-50-361-28-24; fax: +31-50-361-48-62
    • ,
  • H.J Hoekstra

      Affiliations

    • Department of Surgical Oncology, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • H Hollema

      Affiliations

    • Department of Pathology, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • E van den Berg

      Affiliations

    • Department of Clinical Genetics, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • N Zwart

      Affiliations

    • Department of Pathology, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • R.J Scheper

      Affiliations

    • Department of Pathology, Free University Hospital, Amsterdam, The Netherlands
    • ,
  • W.M Molenaar

      Affiliations

    • Department of Pathology, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands

Received 13 November 2002 ,Accepted 15 November 2002.

References 

  1. Weiss SW, Goldblum JR. Enzinger and Weiss's soft tissue tumors. 4th edn.. St. Louis: Mosby; 2001;
  2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J. Clin. 2002;2001:52; 23-47
  3. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J. Clin. Oncol. 1996;14:1679–1689
  4. van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al.  Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma (an analysis of 2,185 patients treated with anthracycline-containing first-line regimens—a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study). J. Clin. Oncol. 1999;17:150–157
  5. Coindre JM, Terrier P, Guillou L, et al.  Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. Cancer. 2001;91:1914–1926
  6. Coindre JM, Terrier P, Bui NB, et al.  Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J. Clin. Oncol. 1996;14:869–877
  7. Trojani M, Contesso G, Coindre JM, et al.  Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int. J. Cancer. 1984;33:37–42
  8. Coindre JM, Trojani M, Contesso G, et al.  Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer. 1986;58:306–309
  9. Antman K, Crowley J, Balcerzak SP, et al.  An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 1993;11:1276–1285
  10. Edmonson JH, Ryan LM, Blum RH, et al.  Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 1993;11:1269–1275
  11. Santoro A, Tursz T, Mouridsen H, et al.  Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first- line treatment of advanced soft tissue sarcomas (a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group). J. Clin. Oncol. 1995;13:1537–1545
  12. Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin. Oncol. 1997;24:556–560
  13. Borst P, Schinkel AH. Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet. 1997;13:217–222
  14. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994;54:357–361
  15. Scheper RJ, Broxterman HJ, Scheffer GL, et al.  Overexpression of a M(r) 110,000 vesicular protein in non-P- glycoprotein-mediated multidrug resistance. Cancer Res. 1993;53:1475–1479
  16. Cole SP, Sparks KE, Fraser K, et al.  Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994;54:5902–5910
  17. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Scheper RJ. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr. Opin. Oncol. 2000;12:550–556
  18. Izquierdo MA, Shoemaker RH, Flens MJ, et al.  Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer. 1996;65:230–237
  19. Raaijmakers HG, Izquierdo MA, Lokhorst HM, et al.  Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood. 1998;91:1029–1036
  20. Nijhuis PH, Schaapveld M, Otter R, Molenaar WM, van der Graaf WT, Hoekstra HJ. Epidemiological aspects of soft tissue sarcomas (STS)–consequences for the design of clinical STS trials. Eur. J. Cancer. 1999;35:1705–1710
  21. Association of Directors of Anatomic SurgicalPathology. Recommendations for the reporting of soft tissue sarcoma. Virchows Arch. 1999;434:187–191
  22. Komdeur R, Plaat BEC, Hoekstra HJ, et al.  Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer. 2001;91:1940–1948
  23. Flens MJ, Izquierdo MA, Scheffer GL, et al.  Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994;54:4557–4563
  24. Izquierdo MA, van der Zee AG, Vermorken JB, et al.  Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J. Natl. Cancer Inst. 1995;87:1230–1237
  25. Kuttesch JF, Parham DM, Luo X, et al.  P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J. Clin. Oncol. 1996;14:886–900
  26. Chan HS, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein (prognostic correlation in soft tissue sarcoma of childhood). J. Clin. Oncol. 1990;8:689–704
  27. Nakanishi H, Myoui A, Ochi T, Aozasa K. P-glycoprotein expression in soft-tissue sarcomas. J. Cancer Res. Clin. Oncol. 1997;123:352–356
  28. Levine EA, Holzmayer T, Bacus S, et al.  Evaluation of newer prognostic markers for adult soft tissue sarcomas. J. Clin. Oncol. 1997;15:3249–3257
  29. Jimenez RE, Zalupski MM, Frank JJ, Du W, Ryan JR, Lucas DR. Multidrug resistance phenotype in high grade soft tissue sarcoma (correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy). Cancer. 1999;86:976–981
  30. Oda Y, Schneider-Stock R, Rys J, Gruchala A, Niezabitowski A, Roessner A. Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas. J. Cancer Res. Clin. Oncol. 1996;122:161–165
  31. Stein U, Shoemaker RH, Schlag PM. MDR1 gene expression (evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas). Eur. J. Cancer. 1996;32A:86–92
  32. Coley HM, Verrill MW, Gregson SE, Odell DE, Fisher C, Judson IR. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur. J. Cancer. 2000;36:881–888
  33. Plaat BEC, Hollema H, Molenaar WM, et al.  Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors (differences in clinical outcome and expression of multidrug resistance proteins). J. Clin. Oncol. 2000;18:3211–3220
  34. Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest. 2002;20:605–612
  35. Maki RG, Segal NH, Pavlidis P, et al. Classification of high-grade adult soft-tissue sarcomas (STS) by oligonucleotide array analysis. Proc ASCO 2002, abstract 1611.
  36. Kusakabe H, Iwasaki H, Sano K, Kiyokane K. Expression of lung resistance protein in epithelioid sarcoma in vitro and in vivo. Arch. Dermatol. Res. 2000;292:292–300
  37. Cocker HA, Pinkerton CR, Kelland LR. Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines. Br. J. Cancer. 2000;83:338–345
  38. Plaat BEC, Molenaar WM, Sagrudny J, et al.  The 16p11 breakpoint in myxoid liposarcomas might affect the expression of the LRP gene on 16p11.2 encoding the multidrug resistance associated major vault protein. Eur. J. Clin. Invest. 2000;30:447–453
  39. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC Cancer Staging Handbook. 6th Ed.. Heidelberg: Springer-Verlag; 2002;

PII: S0959-8049(03)00029-7

doi: 10.1016/S0959-8049(03)00029-7

European Journal of Cancer
Volume 39, Issue 7 , Pages 909-916 , May 2003

Article Tools

* Image Usage & Resolution